IXHL

Incannex Healthcare Inc. is a clinical-stage pharmaceutical development company focused on developing novel cannabinoid-based medications and psychedelic medicine therapies. The company is advancing a pipeline of drug candidates targeting conditions including obstructive sleep apnea, traumatic brain injury, rheumatoid arthritis, and inflammatory bowel disease. Incannex conducts clinical trials across multiple jurisdictions and is working to establish regulatory pathways for its cannabinoid pharmaceutical products. The company is headquartered in Australia with operations in the United States.